The Global Precision Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the Precision Medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest Precision Medicine agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Precision Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Precision Medicine partnering deals.
The report presents financial deal term values for Precision Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Precision Medicine partnering field; both the leading deal values and most active Precision Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1,200 online deal records of actual Precision Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Precision Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Precision Medicine dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Precision Medicine deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Precision Medicine dealmaking with a brief summary followed by a comprehensive listing of Precision Medicine deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014. The chapter is organized by specific Precision Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Precision Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Precision Medicine partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Precision Medicine technologies and products.
Key benefits Global Precision Medicine Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits: In-depth understanding of Precision Medicine deal trends since 2014 Access to headline, upfront, milestone and royalty data Detailed access to actual Precision Medicine contracts entered into by leading biopharma companies Identify most active Precision Medicine dealmakers since 2014 Insight into terms included in a Precision Medicine partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Precision Medicine Partnering terms and Agreements 2014-2021 is intended to provide the reader with an in-depth understanding and access to Precision Medicine trends and structure of deals entered into by leading companies worldwide.
Precision Medicine Partnering Terms and Agreements includes: Trends in Precision Medicine dealmaking in the biopharma industry since 2014 Analysis of Precision Medicine deal structure Access to headline, upfront, milestone and royalty data Access to Precision Medicine contract documents Leading Precision Medicine deals by value since 2014 Most active Precision Medicine dealmakers since 2014
In Global Precision Medicine Partnering Terms and Agreements 2014-2021, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Precision Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 1,200 Precision Medicine deals.
Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
REPORT OBJECTIVES The report “Eggshell Membrane Derivatives Market: Global Market Intelligence (2020-2030) provides market intelligence on the different market segments, based on Market Dynamics, Distribution Channel, Product type, and geography. Market size and forecast (2020-2030) has been provided in the report. The...
“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and...
Global Academic and Non-Profit Partnering Terms and Agreements 2015 to 2021 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This...
Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) - Drugs in Development, 2021 provides in...
The global cell dissociation market size is projected to reach USD 561 million by 2026 from USD 282 million in 2021, at a CAGR of 14.7% during the forecast period. The growth in this market is attributed to the prevalence of cell based research, the increasing number of pharmaceutical and biotechnology companies. Moreover, the growth opportunities...
The Global Stem Cell Partnering Terms and Agreements 2010-2021 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Deal terms analysis Partnering agreement structure Partnering...
243 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
162 pages •
By Global Industry Analysts
• Apr 2021
- Global Stem Cells Market to Reach $15.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Stem Cells estimated at US$9.1 Billion in the year 2020, is projected to reach a revised size of US$15.1 Billion by 2027, growing at aCAGR of 7.4% over the period 2020-2027. Adult Stem Cells, one of...
The microcarriers market is projected to reach USD 2.9 billion by 2026 from USD 1.7 billion in 2021, at a CAGR of 10.7% during the forecast period. Increasing use of single-use bioreactors for bioprocessing, rising investmnet in R&D for developemnt of vaccines and therapeutic protiens, and increasing government funding for cell and gene therapy. •...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.